Does APLM pay a dividend?

The cached stock data on this page does not show a positive dividend yield for APLM. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does APLM stock do?

Clinical/commercial-stage biopharmaceutical enterprise focused on developing targeted oncology therapies including c-Met inhibitor APL-101 (Vebreltinib), APL-102, and APL-122.

What is APLM stock's price target?

This cached page does not contain a precise model fair value for APLM.

The TradeMates model verdict for APLM is AVOID with an investment score of 27/100. Treat this as a model signal to review, not a personal buy recommendation.

Is APLM a good dividend stock?

APLM is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

APLM (APLM) Stock Analysis

Q: Is APLM stock a good investment?

The cached TradeMates AI model rates APLM as AVOID with an investment score of 27/100. Apollomics faces an acute cash crunch with $3.28M in cash against $10.37M annual burn, implying under 4 months of runway before mandatory dilution. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

Severe liquidity distress with under 4 months of cash runway creates extreme dilution risk despite recent technical price momentum.

Investment score: 27/100

Apollomics faces an acute cash crunch with $3.28M in cash against $10.37M annual burn, implying under 4 months of runway before mandatory dilution.

View the full interactive analysis